Kirr Marbach & Co. LLC IN Makes New $532,000 Investment in Orthofix Medical Inc. (NASDAQ:OFIX)

Kirr Marbach & Co. LLC IN bought a new position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 30,462 shares of the medical device company's stock, valued at approximately $532,000. Kirr Marbach & Co. LLC IN owned 0.08% of Orthofix Medical as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of OFIX. Franklin Resources Inc. lifted its stake in Orthofix Medical by 37.4% during the 3rd quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company's stock valued at $337,000 after acquiring an additional 5,702 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Orthofix Medical by 14.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company's stock valued at $5,073,000 after buying an additional 39,901 shares during the last quarter. Barclays PLC lifted its holdings in shares of Orthofix Medical by 38.8% in the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock valued at $1,912,000 after buying an additional 34,210 shares during the period. HighTower Advisors LLC boosted its stake in shares of Orthofix Medical by 114.9% in the third quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company's stock worth $1,393,000 after buying an additional 47,680 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Orthofix Medical by 480.7% during the third quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company's stock worth $1,318,000 after acquiring an additional 69,848 shares during the period. Hedge funds and other institutional investors own 89.76% of the company's stock.

Insider Buying and Selling at Orthofix Medical

In other news, CEO Massimo Calafiore sold 10,078 shares of the business's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $16.83, for a total transaction of $169,612.74. Following the completion of the transaction, the chief executive officer now directly owns 133,354 shares of the company's stock, valued at approximately $2,244,347.82. The trade was a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Julie Andrews sold 4,655 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares in the company, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,675 shares of company stock valued at $423,238 in the last 90 days. Company insiders own 2.60% of the company's stock.

Orthofix Medical Trading Down 1.7 %

Shares of NASDAQ:OFIX traded down $0.32 during mid-day trading on Friday, reaching $18.33. 161,864 shares of the company were exchanged, compared to its average volume of 180,521. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The firm's 50-day simple moving average is $18.07 and its 200 day simple moving average is $17.08. The firm has a market cap of $700.39 million, a price-to-earnings ratio of -5.86 and a beta of 1.10.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last released its earnings results on Thursday, November 7th. The medical device company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.57). Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. The firm had revenue of $196.61 million during the quarter, compared to analyst estimates of $196.60 million. During the same period in the prior year, the firm earned ($0.77) earnings per share. Equities research analysts forecast that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on OFIX. Canaccord Genuity Group assumed coverage on Orthofix Medical in a research report on Wednesday, January 22nd. They issued a "buy" rating and a $24.00 price objective on the stock. Stifel Nicolaus raised shares of Orthofix Medical from a "hold" rating to a "buy" rating and increased their price target for the stock from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm restated a "buy" rating and set a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Finally, StockNews.com raised shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Friday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Orthofix Medical presently has a consensus rating of "Moderate Buy" and an average price target of $23.33.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.